In contrast to cardiorenal syndrome ... should the enhancement of cardiovascular death initiated by kidney disease be termed 'renocardiac syndrome'? As the kidney is the primary regulator of ...

Cardiorenal syndrome (CRS) commonly occurs during treatment of acute decompensated heart failure (ADHF) and is associated with poor clinical outcome. The pathophysiology of CRS entails a complex ...

Acute cardiorenal (type 1) Acute worsening of heart function (AHF-ACS) leading to kidney injury and/or dysfunction Acute decompensated heart failure, acute coronary syndrome Chronic cardiorenal ...

Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic ...

Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic kidney disease at risk for progression, according to a study published ...

This is an important, but poorly understood, cause of morbidity and mortality in human and veterinary patients. The Comparative Cardiorenal Research Group is a unique collaboration between medical and ...

Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart ...

Differences in characteristics of the overall T1D population and those newly prescribed the medications are often associated with elevated cardiorenal risk profiles, suggesting use of these newer ...

Scpharmaceuticals ( (SCPH) ) has released its Q3 earnings. Here is a breakdown of the information Scpharmaceuticals presented to its investors.